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Abstract 
 
Introduction: Our recent studies have indicated that acetylcholine (ACh) protects 
cardiomyocytes from prolonged hypoxia through activation of the 
PI3K/Akt/HIF-1D/VEGF pathway, and that cardiomyocyte-derived VEGF promotes 
angiogenesis in a paracrine fashion. These results suggest that a cholinergic system 
plays a role in modulating angiogenesis. Therefore, we assessed the hypothesis that the 
cholinergic modulator donepezil, an acetylcholinesterase inhibitor utilized in 
Alzheimer’s disease, exhibits beneficial effects, especially on the acceleration of 
angiogenesis. 
Methods: We evaluated the effects of donepezil on angiogenic properties in vitro and in 
vivo, using an ischemic hindlimb model of D7 nicotinic receptor-deleted mice (D7 KO) 
and wild type mice (WT).  
Results: Donepezil activated angiogenic signals, i.e., HIF-1D and VEGF expression, 
and accelerated tube formation in human umbilical vein endothelial cells (HUVECs). 
ACh and nicotine upregulated signal transduction with acceleration of tube formation, 
suggesting that donepezil promotes a common angiogenesis pathway. Moreover, 
donepezil-treated WT exhibited rich capillaries with enhanced VEGF and PCNA 
endothelial expression, recovery from impaired tissue perfusion, prevention of 
ischemia-induced muscular atrophy with sustained surface skin temperature in the limb, 
and inhibition of apoptosis independent of the D7 receptor. Donepezil exerted 
comparably more effects in D7 KO in terms of angiogenesis, tissue perfusion, 
biochemical markers, and surface skin temperature. Donepezil concomitantly elevated 
VEGF expression in intracardiac endothelial cells of WT and D7 KO, and further 
increased choline acetyltransferase (ChAT) protein expression, which is critical for ACh 
synthesis in endothelial cells. 
Conclusion: The present study concludes that donepezil can act as a therapeutic tool to 
accelerate angiogenesis in cardiovascular disease patients. 
 
 
Keywords: angiogenesis, vascular endothelial growth factor, acetylcholinesterase 
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Introduction 
 
Studies investigating the effects of vagal nerve stimulation (VS) on heart failure have 
suggested VS as a candidate for a therapeutic modality in heart failure because VS 
suppresses infarction-induced fatal arrhythmia and progression of ventricular 
remodeling [1,2]. However, the precise mechanisms remain to be fully elucidated. 
To further investigate the underlying mechanisms of the VS effects, we have focused 
on disclosing the pleiotrophic effects of acetylcholine (ACh) and revealed that ACh 
prevents cardiomyocytes from persistent hypoxia-induced cell death, and have 
ultimately presented a new concept regarding ACh as a trophic factor. Our recent study 
demonstrated that ACh directly transduces cell survival signal through the muscarinic 
receptor, activates the PI3K/Akt/HIF-1D/VEGF pathway, inhibits collapse of 
mitochondrial membrane potential, and inactivates caspase-3 in cardiomyocytes 
subjected to hypoxia [3]. Because both survival and angiogenic pathways share 
common signaling molecules through HIF-1D/VEGF, these results prompted us to 
speculate the involvement of ACh in modulation of angiogenesis. 
Furthermore, ACh transduces signals through nitric oxide (NO) production, and NO 
plays a key role in angiogenesis [4-8]. Specifically, according to our previous study, the 
NO donor S-nitroso-N-acetylpenicillamine activates the PI3K/Akt/HIF-1D pathway to 
increase VEGF expression in cardiomyocytes, and VEGF derived from cardiomyocytes 
accelerates tube formation in human umbilical endothelial cells (HUVECs), i.e., in vitro 
angiogenesis [4].  
In contrast to these positive results, few in vivo studies have demonstrated the effects 
of systemically administered ACh because of its severe side effects including induction 
of bronchospasm and airway mucus hypersecretion. To circumvent this, we used 
donepezil, an acetylcholinesterase inhibitor and anti-Alzheimer’s drug, that elevates 
local levels of ACh without such adverse effects [9,10]. In addition, we tested the effect 
of donepezil in a murine hindlimb ischemia model. To extensively investigate the effect 
of donepezil, we used D7 nicotinic receptor-deleted mice (D7 KO) suffering from 
impaired angiogenesis with characteristic mechanisms [11-13]. In the present study, we 
demonstrated a novel effect of donepezil on angiogenesis, i.e., acceleration of 
angiogenesis. 
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Materials and Methods 
 
Murine hindlimb ischemia model and donepezil administration 
Male C57BL6/J mice (WT) (n = 45) and D7 KO (n = 26) aged 10 - 12 weeks were used. 
After anesthesia with pentobarbital sodium (30 mg/kg), the left femoral artery was 
completely ligated at its proximal end. Ligation was verified to be successful by pallor 
of the left foot. Donepezil (5 mg/kg/day) dissolved in drinking water (50 mg/L) was 
orally administered ad lib for 4 weeks. This dose was initially determined to clearly 
show the expected effects without producing adverse effects in the mice.  
To investigate the involvement of cholinergic receptors on the effects of donepezil in 
terms of angiogenesis in vivo and to compare it with WT treated with donepezil alone, 
further donepezil-treated WT were divided into 3 subgroups (n = 6 - 9 in each group) 
receiving one of the following treatments for 4 weeks: (a) D-bungarotoxin (14 
Pg/kg/day by i.m. on the flank), (b) mecamylamine (2.1 mg/kg/day i.m. on the flank), 
and (c) atropine (5 mg/kg/day p.o.) [14]. Another experimental study was conducted on 
D7 KO with a lower dose (0.083 mg/kg/day) using the same experimental schedule (n = 
9). This lower dose was comparable with that prescribed for patients. At the end of the 
treatment period, the heart and quadriceps femoris muscle were excised for experiments. 
Our preliminary study verified that even higher dose of donepezil, 5 mg/kg/day, does 
not downregulate heart rate or blood pressure.  
 
Angiography using indocyanine green dye 
To functionally evaluate the effects of donepezil on murine angiogenesis, angiography 
was performed using indocyanine green (ICG) (Sigma-Aldrich, St. Louis, MO, USA), 
which clearly visualize tissue perfusion in the hindlimb. After anesthesia with 
pentobarbital sodium, both lower extremities were shaved. The field was illuminated by 
a LED-fluorescence imaging device, and ICG was administered intravenously (0.3 
mg/kg). After a bolus ICG injection, real-time imaging analysis was performed using an infrared 
camera, and recorded with a digital camcorder for an optimized time. Our preliminary 
studies identified that ICG angiography in the hindlimbs initially revealed an angiogram, 
followed by a perfusion phase, when the fluorescence signals in the perfused tissue were 
simultaneously and homogeneously increased in both hindlimbs. After recording, the 
fluorescence intensity in the hindlimb was evaluated. Therefore, to evaluate perfusion in 
an ischemic hindlimb, the interested regions were selected from both right and left 
hindlimbs. The fluorescence signals of the left hindlimb in the perfusion phase were 
compared with those of the right, using NIH image software, and it revealed laterality in 
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the ICG signal intensity. The time when the signal difference between the right and left 
was extremely evident was selected. 
  
Evaluation of the relative blood flow using fluorescent microspheres 
According to previous studies using fluorescent microspheres [15,16], we evaluated the 
relative blood flow between the left and right hindlimbs in mice. Briefly, after 
anesthesia, 200 PL of green FluoSphere fluorescent microspheres (15 Pm, Molecular 
Probes, Invitrogen, Carlsbad, CA, USA) were administered within 1 min, followed by 
immediate sampling of blood and bilateral quadriceps femoris muscles. These samples 
were weighed accurately and incubated in 4 M KOH containing 2% of Tween 80 at 
70ºC for 24 h. After measuring the fluorescence, the ratio of the fluorescence between 
the left and right hindlimbs, corrected by the tissue weight, was compared. 
 
Thermography 
One day after surgery, an initial temperature evaluation was performed in the hindlimbs 
using infrared thermography (MobIR M4 Thermal Camera, Wuhan Guide Infrared 
Technology Co., Ltd. China). The skin temperature of the mice under anesthesia was 
measured 3 times. Thereafter, for each mouse, temperature was evaluated 3 times by 
thermography during 4 weeks. The temperature distribution in the hindlimbs was 
compared between donepezil-treated and untreated mice, and standardized by each 
non-ligated hindlimb as a reference. The laterality in temperature, represented by the 
ratio between the left and right hindlimb temperature, was evaluated. 
 
Immunohistochemistry  
The heart and quadriceps femoris muscle were excised and fixed in 4% 
paraformaldehyde. Some muscle samples were routinely processed, paraffin-embedded, 
cut into 4 μm sections, and stained with hematoxylin and eosin. The number of nuclei in 
capillary-like structures per HPF were counted in randomly selected fields (9 fields per 
section). Other samples were used for immunohistochemical study using the Ventana 
automated immunohistochemistry system (Discovery TM, Ventana Medical System, 
Inc., Tucson, AZ, USA). Antigen retrieval was performed for 60 min in a preheated 
Dako Target Retrieval Solution (pH 6.0) using a microwave, followed by inhibition of 
intrinsic peroxidase, blocking, and the reaction with a primary antibody. VEGF and 
PCNA immunoreactivities were identified using a polyclonal anti-VEGF antibody at 
1:100 (sc-152) (Santa Cruz Biotechnology, CA, USA) and a monoclonal anti-PCNA 
antibody at 1:2000 (Abcam Inc., Cambridge, MA, USA), respectively, based on the 
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streptavidin-biotin-peroxidase reaction. 
 
Western blotting 
Whole muscle cell lysates were fractionated by SDS–PAGE and transferred onto 
membranes (Millipore Corp., Bedford, MA, USA). The membranes were incubated 
with polyclonal antibodies against VEGF (Santa Cruz Biotechnology), ChAT (Millipore 
Corp., Bedford, MA, USA), cleaved caspase-3 (Cell Signaling Technology, Danvers, 
MA, USA), diluted at 1:500, or with monoclonal antibodies against HIF-1D (Novus 
Biologicals, Inc., Littleton, CO, USA), pFlk-1 (Tyr 951, Santa Cruz Biochemistry), 
diluted at 1:500, D-tubulin (LAB VISION, Fremont, CA, USA) and PCNA (Abcam 
Inc.) diluted at 1:2000. Human umbilical vein endothelial cells (HUVECs), cultured in 
supplemented EGM-2 culture medium (Cambrex, Walkersville, MD, USA) on 24-well 
plates, were harvested with sample buffers. Similarly, the blotted membranes were 
incubated with a polyclonal anti-ChAT antibody (Millipore) diluted at 1:500, which 
detects several bands with a M.W. of 68 - 70kDa. Each antibody was used in 
conjunction with a horseradish peroxidase-conjugated secondary antibody. For in vitro 
studies, each experiment was independently performed 3 times. After that, the 
densitometry analysis was performed. 
 
Reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was extracted from cells, and total RNA (1 Pg) was reverse-transcribed to 
obtain single-stranded cDNA using a kit. Specific human cholinergic receptor primers 
were designed according to previous studies [17, 18]. PCR amplification was performed 
with 40 cycles of the reaction and annealing temperatures of 60ºC. Primer sequences 
were as follows:  
m1, TGAGGGCTCACCAGAGACT (forward),  
GTCCAGGTGAGGATGAAGG (reverse);  
m2, ACAAGGAAGGATAGTGAAGCC (forward),  
CATCTCCATTCTGACCTGAAG (reverse);  
D4, CTCACCGTCCTTCTGTGTC (forward),  
CTGGCTTTCTCAGCTTCCAG (reverse);  
D7, AGGCCACCTCATCAGCAG (forward),  
GTACGCTGGTTTCCCTTTGA (reverse);  
GAPDH, CGTCTTCACCACCATGGAGA (forward), 
   CGGCCATCACGCCACAGCTT (reverse). 
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Cell culture 
HUVECs or human aorta endothelial cells (HAECs) were cultured in EGM-2 culture 
medium (Cambrex), supplemented with heparin, IGF-I, VEGF, bFGF, EGF, 
hydrocortisone, FBS, and ascorbic acid, according to the manufacturer’s instruction. 
The final concentration of each reagent was as follows: 1 PM of donepezil (Eisai Co., 
Ltd., Tokyo, Japan), 0.1 PM of nicotine, which has been reported to possess angiogenic 
property [11-13], and 100 PM of ACh (Sigma-Aldrich, St. Louis, MO, USA). 
To investigate the effects on tube formation, in vitro angiogenesis, HUVECs were 
cultured on Matrigel with complete growth factors (Becton Dickinson Labware, 
Bedford, MA, USA) using 96-well plates. HUVECs (1 u 104 cells) were seeded on 
Matrigel (50%)-coated wells and incubated for 24 h in DMEM with 20% FBS, 25 Pg/ml 
endothelial cell growth supplement (Upstate, Lake Placid, NY, USA), 10 U/ml heparin 
and any one of the study agents. The number of tubes per low power field in each well 
was counted and compared. 
 
MTT activity 
To evaluate HUVEC proliferation, we measured the reduction activity of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). One hour before 
sampling, MTT reagents (10 PL) were added to the culture medium (100 PL), incubated, 
and the absorbance at 450 nm was measured (Cell Counting Kit-8; Dojindo, Kumamoto, 
Japan), according to the manufacturer’s protocol. 
 
Caspase 3/7 activity 
According to the manufacturer’s protocol (Promega, Madison, WI, USA), HUVECs 
treated with or without donepezil were cultured with an equal volume of Caspase-Glo 
3/7 reagent for 3 h, followed by measuring the luminescence of each sample using the 
luminometer manufacturer’s protocol. 
 
Statistical analysis 
The data are presented as means r S.E. The mean values between the 2 groups were 
compared using the unpaired Student’s t-test. Differences among data for the in vitro 
studies were assessed by the Kruskal-Wallis test for multiple comparisons, followed by 
Scheffe’s post-hoc test. Differences were considered significant at P < 0.05. 
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Results 
 
Donepezil activates angiogenic signals and accelerates tube formation in vitro. 
Donepezil transduces angiogenic signals. In the normoxic condition, donepezil (1 PM) 
elevated the HIF-1D protein level, and then augmented expression of VEGF and 
activated phosphorylation of Flk-1, VEGF type 2 receptor (Figure 1A), which composes 
critical angiogenic signaling. Correspondingly, donepezil enhanced tube formation 
(Figure 1B) in HUVECs within 24 h (12.8 r 0.6 in donepezil-treated HUVECs vs. 6.7 r 
0.4 in control, P < 0.01), suggesting that donepezil is capable of accelerating 
angiogenesis. This effect of donepezil was inhibited by the muscarinic receptor 
antagonist atropine (100 PM) (0.7 r 0.2, P <0.01) and the selective D7 nicotinic 
receptor antagonist D-bungarotoxin (0.1 PM) (2.0 r 0.6, P <0.01) (Figure 1B). 
 The mechanisms of donepezil-induced acceleration of angiogenesis were revealed by 
the effect of ACh and nicotine, which have been reported to promote angiogenesis 
[11-13], on HUVECs. ACh and nicotine shared the same angiogenic signals (Figure 1C). 
Moreover, ACh accelerated HUVEC tube formation within 24 h (16.8 r 0.9 with 100 
PM of ACh vs. 7.3 r 0.5 control, P < 0.01) (Figure 1D); however, it was markedly 
suppressed by atropine (100 PM) (2.8 r 0.8, P < 0.01) and D-bungarotoxin (0.1 PM) 
(2.7 r 0.6, P < 0.01) (Figure1D). Similarly, ACh accelerated tube formation in HAECs, 
which was partially suppressed by atropine (data not shown). These results suggest that 
ACh promotes in vitro angiogenesis through angiogenic signal transduction and that the 
signal is mediated via both nicotinic and muscarinic receptors.  
 
Donepezil promotes angiogenesis and suppresses ischemia-induced muscular 
atrophy in a murine hindlimb ischemia model 
In untreated WT, muscular atrophy of the left quadriceps femoris muscle was evident 
within 4 weeks after hindlimb ischemia due to femoral artery ligation (Figure 2A, 
arrowheads in the left panel). The temperature in the left ischemic limb increased 
gradually during the follow-up; however, it did not comparably recover to the level of 
the contralateral hindlimb (Figure 2B). The ratio of skin temperature in the left hindlimb 
to that in the right hindlimb, the laterality in temperature, decreased to 0.50 r 0.04 soon 
after ligation, followed by an elevation to 0.81 r 0.02. In contrast, donepezil-treated 
mice did not suffer from severe muscular atrophy (Figure 2A). The weight ratio of the 
left hindlimb to the right was 1.02 r 0.04 (P < 0.05, n = 10) in donepezil-treated mice, 
compared with 0.85 r 0.01 (n = 10) in control untreated mice (Figure 2A). Furthermore, 
the laterality of temperature increased to 0.95 r 0.01 with donepezil treatment (P < 0.01 
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vs. control) (Figure 2B). A pathological study revealed that, compared to untreated 
muscle (left in control, Figure 2C), the number of nuclei in treated muscle increased 
along with more capillary-like structures (Figure 2C). The number of nuclei per field in 
the donepezil-treated left hindlimb increased significantly compared to that in 
non-treated and ischemic hindlimbs (17.8 r 1.4 vs. 8.6 r 0.9, P < 0.01, n = 9). The 
immunohistochemical study showed that cells positive for VEGF immunoreactivity 
were sparsely detected in the control. In contrast, dense VEGF signals were detected in 
the donepezil-treated muscle coincidence with small capillaries (Figure 2C). Western 
blot analysis showed that the expression of both HIF-1D (318.4 r 29.9 vs. 100.0 r 6.7 in 
the control, P < 0.01, n = 9) and VEGF (144.5 r 2.9 vs. 99.8 r 9.9 in the control, P < 
0.01, n = 9) in the left hindlimbs from donepezil-treated mice were higher than that in 
the left hindlimbs from the control (Figure 2C).  
 These effects of donepezil were also evaluated using D-bungarotoxin, mecamylamine, 
and atropine (Figure 2D). VEGF protein expression in the left hindlimb was elevated by 
donepezil (P < 0.05); however, donepezil treatment combined with D-bungarotoxin did 
not suppress VEGF expression. Mecamylamine and atropine showed a trend toward 
reduced VEGF expression, but could not diminish it completely (not significant vs. 
donepezil). Similarly, PCNA expression was elevated by donepezil (P < 0.01), the level 
of which was not diminished by D-bungarotoxin (P < 0.05); however, mecamylamine (P 
< 0.05 vs. donepezil) and atropine (P < 0.01 vs. donepezil) blunted PCNA expression. 
The VEGF and PCNA immunoreactive signals were especially localized at endothelial 
cells (Figure 2E). Endothelial cells with both VEGF- and PCNA-positive signals were 
evident in left hindlimbs of donepezil-treated mice, compared to that in controls. The 
protein level of cleaved caspase-3, an indicator of caspase-3 activation, was drastically 
reduced by donepezil (P < 0.05), but was not affected by D-bungarotoxin, 
mecamylamine or atropine (not significant vs. donepezil). Furthermore, the laterality of 
temperature sustained by donepezil did not diminish with each antagonist (P < 0.01 vs. 
control, but not significant vs. donepezil) (Figure 2F). These results suggest that 
donepezil activates angiogenesis in a hindlimb ischemia model with upregulated 
angiogenic factors, enhanced proliferation, inhibition of apoptosis, and suppressed 
ischemia-induced muscular atrophy; however, partly not through already known 
cholinergic receptors.      
Angiography with ICG revealed a marked increase in perfusion with donepezil 
treatment, which was comparable to the non-ischemic contralateral limb (1.08 r 0.6 and 
1.00 r 0.84 vs. 0.74 r 0.27, P < 0.01). Furthermore, a blood flow assay using 
fluorescent microspheres revealed that donepezil enhanced blood flow recovery (124.9 
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r 15.8 in donepezil vs. 59.0 r 12.2 in control, P < 0.05, n = 5 in each) (Figure 2G), 
suggesting that donepezil functionally recovered tissue perfusion in the ischemic 
hindlimb.  
 
Donepezil accelerates angiogenesis even in D7 KO with hindlimb ischemia  
Previous reports using D7 KO indicated that a nicotinic receptor is responsible for 
angiogenesis [11-13]. Therefore, to investigate whether the angiogenic effects of 
donepezil are mediated through D7 nicotinic receptors, we studied the effects of 
donepezil on peripheral limb ischemia using these mice. Compared with control 
untreated D7 KO (0.93 r 0.02, n = 13), donepezil-treated D7 KO surprisingly attenuated 
ischemia-induced muscular atrophy with a leg-weight ratio of 1.01 r 0.04 (P < 0.01, n = 
13) (Figure 3A). ICG angiography revealed that tissue perfusion in the left hidlimb was 
sustained in donepezil-treated D7 KO (1.23 r 0.10 vs. 0.70 r 0.27 in control, P < 0.01), 
as supported by the microsphere assay (117.4 r 9.7 vs. 70.4 r 10.7 in control, P < 0.05, 
n = 5 in each) (Figure 3B). VEGF expression in quadriceps femoris muscle from 
donepezil-treated D7 KO was more elevated (191.4 r 10.0 vs. 100 r 1.3 in control, P < 
0.01) (Figure 3C) and the increased immunoreactivity was also detected in the treated 
muscle. Finally, donepezil accelerated temperature recovery in ischemic hindlimbs 
(Figure 3D). Compared with the laterality in temperature in WT 4 weeks after ligation, 
that in D7 KO decreased further to 0.71 r 0.03 (vs. 0.81 r 0.02 in WT, P < 0.05); 
however, treatment with donepezil elevated the ratio to 0.98 r 0.02 even in D7 KO (P < 
0.01). 
The lower dose of donepezil, 0.083 mg/kg/day, which is comparable to that used in 
clinical settings, was also effective for accelerating in vivo angiogenesis (the laterality in 
temperature 0.96 r 0.04, P < 0.01) (Figure 3E). Taken with the in vivo data using 
D-bungarotoxin, these results also suggest that donepezil rescues ischemic hindlimbs 
independent of the D7 nicotinic receptor. 
  
Donepezil augments VEGF expression in the heart and ChAT protein expression in 
endothelial cells 
In addition to the ischemic hindlimbs, donepezil also enhanced VEGF signals in the WT 
heart, compared to untreated WT (Figure 4A), as supported by Western blot analysis 
(181.8 r 4.2% vs. 100.0 r 0.6% in control, P < 0.01). Similar donepezil effects on 
VEGF production in the heart were observed in D7 KO (Figure 4B). Compatible with 
VEGF immunoreactivity in the hindlimb, the immunohistochemical study with the 
anti-VEGF antibody showed positive signals with capillary-like appearance in the heart 
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(Figure 4A, 4B). 
HUVECs were treated with 1 PM donepezil to study whether donepezil modulates 
ACh synthesis in endothelial cells. Donepezil elevated choline acetyltransferase (ChAT) 
protein expression in HUVECs (248.2 r 3.1% vs. 100.0 r 11.0% in control, P < 0.01) 
(Figure 4C). Because ChAT is a crucial enzyme for ACh synthesis, this suggests that 
donepezil regulates ACh level in endothelial cells. During treatment with donepezil, 
cholinergic receptor mRNAs in HUVECs were also upregulated. RT-PCR showed that 
m2, D4, and D7 mRNA expression were increased by donepezil, compared with D3 and 
GAPDH mRNA expression (Figure 4D). Furthermore, in HUVECs treated with 
donepezil for 24 h, caspase 3/7 activity was suppressed when apoptosis was induced by 
growth factor withdrawal (69.3 r 3.8 % vs. control, P < 0.01, n = 6) (Figure 4E). In 
contrast, donepezil showed only a trend toward increased MTT activity. Taken with the 
in vivo results, these in vitro data suggest that donepezil plays a role in inhibiting 
apoptosis and accelerating proliferation. 
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Discussion 
 
The present study indicates 2 novel and critical points involved in an angiogenesis 
regulating system. First, ACh possessed angiogenic effects on endothelial cells, with 
increased HIF-1D expression, followed by elevated VEGF expression and accelerated 
tube formation, suggesting that ACh modulates intrinsic angiogenesis-responsible 
machinery in endothelial cells. Second, donepezil enhanced angiogenesis by activating 
the similar machinery. Specifically, donepezil activated protein expression of VEGF and 
ChAT, a critical enzyme for de novo ACh synthesis, accelerated endothelial cell 
proliferation, and inhibited apoptosis, partly independent of cholinergic receptors. These 
results suggest that donepezil regulates angiogenesis through a non-hypoxic HIF-1D 
induction pathway, which might be triggered by increased ACh [3,4].  
Donepezil was developed to treat patients with Alzheimer’s disease as an 
acetylcholinesterase inhibitor [12,13]. Donepezil prevents neurons from apoptosis and 
degeneration [19-22] and improves cognitive abilities in patients with Alzheimer’s 
disease [23-25]. However, only few studies have focused on the angiogenesis 
accelerating effects of donepezil [26]. Thus, the present study suggests a novel 
mechanism by which donepezil improves cognitive performance in these patients 
through acceleration of angiogenesis.  
 Our previous study demonstrated that ACh triggers a cell survival signal pathway and 
transactivates HIF-1D-regulated downstream genes, preventing cells from 
hypoxia-induced apoptosis [3]. This prompted us to speculate that cholinergic stimuli 
also possess angiogenesis-promoting effects. ACh clearly promoted angiogenesis and 
acceleration of tube formation; however, it is quite difficult to apply ACh directly to an 
in vivo model, because ACh evokes life threatening side effects, i.e., bronchospasm, 
enhanced secretion, and diarrhea [27,28]. Therefore, instead of ACh, we selected 
donepezil, which is globally used in clinical settings without side effects and has been 
demonstrated to increase tissue ACh levels [9,10,21]. As expected, donepezil promoted 
angiogenesis in vitro and concomitantly activated the HIF-1D/VEGF pathway. These 
effects of donepezil were also confirmed in vivo. Orally administered donepezil 
remarkably increased VEGF and PCNA immunoreactivity in endothelial cells of WT 
ischemic left quadriceps femoris muscles, indicating that donepezil activates 
angiogenesis by upregulating angiogenic signals in endothelial cells. To further study 
whether the effect of donepezil on endothelial cells is dependent on cholinergic 
receptors, donepezil treatment was conducted in the presence of each cholinergic 
receptor antagonist. Unexpectedly, in vivo angiogenesis was not clearly blunted by the 
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antagonists, especially in terms of inhibiting apoptosis. D-Bungarotoxin, a selective D7 
nicotinic receptor antagonist, did not inhibit apoptosis or expression of the angiogenic 
factors VEGF and PCNA, suggesting that donepezil plays an angiogenic role in 
endothelial cells independent of D7 nicotinic receptors. This result was also confirmed 
using D7 KO.  
In this study, we used D7 KO to evaluate the in vivo angiogenic effects of donepezil. 
The studies by Cooke JP et al. utilizing D7 KO indicated that nicotine plays a crucial 
role in angiogenesis [11-13]. They demonstrated an impaired angiogenic effect of 
nicotine in D7 KO [12]. However, except for the D7 nicotinic receptor, there have been 
no studies investigating the role of cholinergic receptors involved in angiogenesis. Only 
D7 KO are available for angiogenesis studies; therefore, we selected them for the 
present study. Our results partially contrasted with Cooke’s in vitro studies because the 
ACh effects were moderately blocked by both D-bungarotoxin and atropine, suggesting 
that the effects of ACh are mediated by 2 receptors, i.e., a nicotinic receptor and a 
muscarinic receptor. This discrepancy might be derived from different HUVEC sources 
used in the studies. We investigated the effects of donepezil using D7 KO expecting that 
the angiogenic effects of donepezil would be blunted. However, donepezil exhibited the 
angiogenesis-accelerating effect even in D7 KO. This result was also compatible with 
that of WT treated with donepezil and D-bungarotoxin. Taken with the WT results, this 
suggests that donepezil directly activates the angiogenic machinery and proliferation 
potency in endothelial cells, leading to inhibition of apoptosis, independent of D7 
nicotinic receptors.  
Because donepezil not only inhibits acetylcholinesterase but also upregulates ChAT, it 
was expected that the intracellular ACh level might be increased. However, even using 
HPLC, ACh levels could not be detected in endothelial cells, although we have thus far 
succeeded in measuring intracellular ACh levels of other cells, such as HEK293 cells, 
H9c2 cells, and primary rat cardiomyocytes [29]. This does not exclude the possibility 
that endothelial cells cannot synthesize ACh. As shown in this study, expression of other 
subtypes of cholinergic receptors, such as m2, D4, and D7, was upregulated by 
donepezil. This effect might also contribute to accelerated angiogenesis in D7 KO. The 
effects of donepezil on in vivo angiogenesis were also observed with a low dose, which 
is compatible with a clinical setting. Our preliminary study has already confirmed that a 
high dose of donepezil has no significant effects on murine heart rate or blood pressure. 
Therefore, it is suggested that low dose donepezil exerts angiogenic effect independent 
of hemodynamic effects.  
Kawashima and Wessler [30,31] speculated that non-neuronal and non-central cells 
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synthesize ACh. Our recent study has demonstrated for the first time that 
cardiomyocytes also possess the intracellular ACh synthesis system, which is 
transcriptionally activated in a positive feedback manner, and donepezil also elevates 
ACh level in cardiomyocytes, which was partly independent of muscarinic receptors 
[29]. These findings also suggest that donepezil exerts its own effects partly 
independent of cholinergic receptors. On the basis of previous studies by Cooke, who 
did not clearly mention an ACh source, together with our recent study [29], it is 
suggested that systemically administered donepezil modulates ACh levels in various 
cells through a cholinergic receptor-dependent or -independent manner, and ACh 
derived from such cells might play a key role in angiogenesis.  
Although donepezil is an acetylcholinesterase inhibitor, a lack of information on its 
receptor and action mechanisms makes our results difficult to interpret. Therefore, it is 
speculated that other mechanisms, i.e., a pathway other than acetylcholinesterase 
inhibition, might be involved in the angiogenesis-accelerating effects, and donepezil 
might directly bind to endothelial cell receptors not yet identified. This remains to be 
clarified.  
In conclusion, we have presented a novel concept that donepezil possesses angiogenic 
properties through enhanced proliferation, increased angiogenic factor expression, and 
inhibition of apoptosis.  
 
 
 15 
Acknowledgement 
This study was supported by a Grant-in-Aid for Scientific Research from Japan Society 
for the Promotion of Science (19590251). 
. 
 16 
References 
1. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve 
stimulation markedly improves long-term survival after chronic heart failure in rats. 
Circulation 2004;109:120-124. 
 
2. Ando M, Katare RG, Kakinuma Y, Zhang D, Yamasaki F, Muramoto K, Sato T. 
Efferent vagal nerve stimulation protects heart against ischemia-induced arrhythmias by 
preserving connexin43 protein. Circulation 2005;112:164-170. 
 
3. Kakinuma Y, Ando M, Kuwabara M, Katare RG, Okudela K, Kobayashi M, Sato T. 
Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and 
hypoxia involving additive non-hypoxic induction of HIF-1alpha. FEBS Lett 
2005;579:2111-2118. 
 
4. Kuwabara M, Kakinuma Y, Ando M, Katare RG, Yamasaki F, Doi Y, Sato T. Nitric 
oxide stimulates vascular endothelial growth factor production in cardiomyocytes 
involved in angiogenesis. J Physiol Sci 2006;56:95-101. 
 
5. Zhao X, Lu X, Feng Q. Deficiency in endothelial nitric oxide synthase impairs 
myocardial angiogenesis. Am J Physiol Heart Circ Physiol 2002;283:H2371-2378. 
 
6. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, Hoskin 
PJ. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a 
phase I study. Lancet Oncol 2007;8:111-118. 
 
7. Williams JL, Cartland D, Hussain A, Egginton S. A differential role for nitric oxide in 
two forms of physiological angiogenesis in mouse. J Physiol 2006;570:445-454. 
 
8. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. Nitric 
oxide regulates angiogenesis through a functional switch involving thrombospondin-1. 
Proc Natl Acad Sci U S A 2005;102:13147-13152. 
 
9. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Koeppe RA, Meltzer 
CC, Constantine G, Davis JG, Mathis CA, Dekosky ST, Moore RY. Degree of inhibition 
of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in 
Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005;76:315-319. 
 17 
 
10. Hatip-Al-Khatib I, Iwasaki K, Yoshimitsu Y, Arai T, Egashira N, Mishima K, Ikeda 
T, Fujiwara M. Effect of oral administration of zanapezil (TAK-147) for 21 days on 
acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats. 
Br J Pharmacol 2005;145:1035-1044. 
 
11. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, 
Cooke JP. Nicotine stimulates angiogenesis and promotes tumor growth and 
atherosclerosis. 
Nat Med 2001;7:833-839. 
 
12. Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP. A novel angiogenic 
pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 
2002;110:527-536.  
 
13. Heeschen C, Weis M, Cooke JP. Nicotine promotes arteriogenesis. J Am Coll 
Cardiol 2003;41:489-496. 
 
14. Li X-W, Wang H. Non-neuronal nicotinic alpha7 receptor, a new endothelial target 
for revascularization. Life Sci 2006;78:1863-1870. 
 
15. Cardinal TR, Hoying JB. A modified fluorescent microsphere-based approach for 
determining resting and hyperemic blood flows in individual murine skeletal muscles. 
Vascular Pharmacol 2007;47:48-56. 
 
16. Hodeige D, de Pauw M, Eechaute W, Weyne J, Heyndrickx GR. On the validity of 
blood glow measurement using colored microspheres. Am J Physiol Heart Circ Physiol 
1999;276:H1150-1158. 
 
17. Elhusseiny A, Cohen Z, Olivier A, Stanimirović DB, Hamel E. (1998) Functional 
acetylcholine muscarinic receptor subtypes in human brain microcirculation: 
identification and cellular localization. J Cereb Blood Flow Metab 1998;19:794-802. 
 
18. Lips KS, Bruggman D, Pfeil U, Vollerthun R, Grando SA, Kummer W. Nicotinic 
acetylcholine receptors in rat and human placenta. Placenta 2005;26:735-746. 
 
 18 
19. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, Akaike A. 
Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against 
glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 
2003;306:772-777.  
 
20. Kimura M, Komatsu H, Ogura H, Sawada K. Comparison of donepezil and 
memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons. 
Neurosci Lett 2005;391:17-21. 
 
21. Kasa P, Papp H, Kasa P Jr, Torok I. Donepezil dose-dependently inhibits 
acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the 
postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. 
Neuroscience 2000;101:89-100. 
 
22. Ginestet L, Ferrario JE, Raisman-Vozari R, Hirsch EC, Debeir T. Donepezil induces 
a cholinergic sprouting in basocortical degeneration. J Neurochem 2007;102:434-440. 
 
23. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and 
global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. 
Donepezil Study Group. Arch Intern Med 1998;158:1021-1031. 
 
24. Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil 
MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with 
more severe Alzheimer's disease: a subgroup analysis from a randomized, 
placebo-controlled trial. Int J Geriatr Psychiatry 2005;20:559-569. 
 
25. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD 
Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in 
patients with moderate Alzheimer's disease. Curr Med Res Opin 2002;18:347-354. 
 
26. Shimizu S, Hanyu H, Iwamoto T, Koizumi K, Abe K. SPECT follow-up study of 
cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's 
disease. J Neuroimaging 2006;16:16-23 
 
27. Fryer AD, Jacoby DB Muscarinic receptors and control of airway smooth muscle. 
Am J Respir Crit Care Med 1998;185: S154-S160. 
 19 
 
28. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors 
and memantine in vascular dementia: a meta-analysis of randomised controlled trials. 
Lancet Neurol 2007;6:782-792. 
 
29. Kakinuma Y, Akiyama T, Sato T. Cholinoceptive and cholinergic properties of 
cardiomyocytes involving an amplification mechanism for vagal efferent effects in 
sparsely innervated ventricular myocardium. FEBS J. 2009;276:5111-5125. 
 
30. Fujii T, Tsuchiya T, Yamada S, Fujimoto K, Suzuki T, Kasahara T, Kawashima K. 
Localization and synthesis of acetylcholine in human leukemic T cell lines. J Neurosci 
Res 1996;44:66-72. 
 
31. Klapproth H, Reinheimer T, Metzen J, Munch M, Bittinger F, Kirkpatrick CJ, Hohle 
KD, Schemann M, Racke K, Wessler I. Non-neuronal acetylcholine, a signalling 
molecule synthezised by surface cells of rat and man. Naunyn Schmiedebergs Arch 
Pharmacol 1997;355:515-523. 
 
 20 
Figure legends 
 
Figure 1 
Donepezil mediates angiogenic signals in HUVECs to activate tube formation. 
(A) Donepezil (1 PM) increased the HIF-1D protein expression level during normoxic 
conditions. This induction of HIF-1D was followed by increased VEGF expression and 
activated phosphorylation of the VEGF receptor-2 Flk-1 in HUVECs (n = 3). (B) 
Donepezil also accelerated tube formation in HUVECs (12.8 r 0.6 tube number per 
field vs. 6.7 r 0.4 in control, P < 0.01, n = 3). In contrast, donepezil-induced tube 
formation was inhibited by atropine (100 PM) or D-bungarotoxine (0.1 PM). Scale bar 
represents 50 Pm. Representative data from 3 experiments are shown for each study. (C) 
ACh (100 PM) and nicotine (0.1 PM) increased HIF-1D and VEGF protein expression. 
(D) Tube formation in untreated HUVECs progressed within 24 h, and ACh markedly 
accelerated tube formation. ACh (100 PM) accelerated tube formation (16.8 r 0.9 in 
100 PM of ACh vs. 7.3 r 0.5, P < 0.01, n = 3). ACh-induced acceleration of tube 
formation was partly suppressed by atropine (100 PM) (2.8 r 0.8, P < 0.01, n = 3) and 
D-bungarotoxine (0.1 PM) (2.7 r 0.6, P < 0.01, n = 3). Scale bars represent 100 Pm. 
Representative data from 3 experiments are shown for each study (D). 
 
Figure 2 
Donepezil promotes angiogenesis in C57 BL6/J wild-type mice (WT) suffering from 
left hindlimb ischemia and suppresses ischemia-induced muscular atrophy and 
reduction of skin temperature. 
(A) WT treated with orally administered donepezil showed comparable muscular 
volume between the right and left hindlimb, even with the left hindlimb ischemia 
(arrowheads in the right panel), compared with untreated WT mice (arrowheads in the 
left panel) (n = 10). (B) Donepezil accelerated skin temperature recovery in the left 
hindlimb within 4 weeks and sustained the skin temperature comparably to the right 
hindlimb. The ratio of skin temperature in the left hindlimb to the right, the laterality in 
the temperature, was increased by donepezil from 0.50 r 0.04 after ligation to 0.95 r 
0.01 (vs. 0.81 r 0.01 in control, P < 0.01, n = 10). (C) Compatible with this, 
donepezil-treated WT mice demonstrated more nuclei aligned with a vasculature-like 
appearance, especially in the left ischemic hindlimb (the right panel in donepezil, Figure 
2C). Magnification: u200. Numbers of nuclei per visual field in the donepezil-treated 
left ischemic hindlimb increased significantly compared to the non-treated hindlimb (P 
< 0.01, n = 9). VEGF immunoreactivity was upregulated by donepezil in the left 
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ischemic hindlimb (the right panel in Figure 2C) compared with the control. Scale bars 
represent 50 Pm. HIF-1D and VEGF protein expression in the left quadriceps femoris 
muscle increased significantly in donepezil-treated WT (P < 0.01, n = 9). (D) This effect 
of donepezil on VEGF signals did not significantly decrease following D-bungarotoxin, 
mecamylamine, or atropine treatment. Inhibition of caspase-3 by donepezil was also not 
attenuated by cholinergic antagonists. The PCNA expression level was elevated by 
donepezil, but not reduced by D-bungarotoxin. (E) Donepezil increased VEGF and 
PCNA immunoreactivity, specifically in endothelial cells, whereas D-bungarotoxin did 
not affect VEGF- and PCNA-positive endothelial cells, as shown in the Western blot 
analysis. (F) Sustained skin temperature by donepezil was not blunted by 
D-bungarotoxin, mecamylamine, or atropine (P < 0.01 vs. control, respectively). (G) 
ICG angiography revealed comparable tissue perfusion between the right and left 
hindlimbs in donepezil-treated WT (1.00 r 0.84 vs. 1.08 r 6.1; not significant, NS, n = 
3) (arrowheads in the right panel). In contrast, untreated WT mice showed lower tissue 
perfusion in the left hindlimb (0.74 r 0.27 vs. 1.00 r 0.43, P < 0.01, n = 3) (arrowheads 
in the left panel). Representative ICG angiography data from 3 experiments are 
presented. A microsphere assay also showed increased blood flow in donepezil-treated 
hindlimbs, evaluated with the ratio of left to right fluorescent signals (115.4 r 19.3 in 
donepezil vs. 75.2 r 7.5 in control, P < 0.05, n = 5).  
 
Figure 3 
Donepezil exhibits comparable angiogenic effects in the ischemic hindlimb model using 
D7 KO mice. 
(A) Donepezil inhibited ischemia-induced muscular atrophy in D7 KO. The ratio of the 
left leg weight to the right leg weight in donepezil-treated mice increased compared 
with untreated mice (n = 13). (B) ICG angiography showed that donepezil attenuated 
ischemia-induced impairment of tissue perfusion (1.23 r 0.10 vs. 0.70 r 0.27, P < 0.01, 
n = 3) compared to untreated D7 KO. Representative ICG angiography data from 3 
experiments are presented. Using a microsphere assay, donepezil inhibited the reduction 
of blood flow (117.4 r 9.7 vs. 70.4 r 10.7 in control, P < 0.05, n = 5 in each). (C) 
VEGF protein expression in the left ischemic hindlimb of donepezil-treated D7 KO 
increased compared with untreated D7 KO (P < 0.01, n=11). More intense VEGF 
immunoreactivity was detected in donepezil-treated D7 KO, especially between each 
muscle fiber. Scale bar represents 50 Pm. (D) Recovery of skin temperature in the left 
ischemic hindlimb of donepezil-treated D7 KO was more accelerated during the 
treatment (arrowheads in the lower panel). The laterality in temperature in D7 KO (0.71 
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r 0.03), which was lower than that in WT (0.81 r 0.02), increased with donepezil (0.98 
r 0.02, P < 0.01, n = 13). In contrast, untreated D7 KO showed poor skin temperature 
recovery (arrowheads in the upper panel). (E) Donepezil, even at a lower dose, inhibited 
the reduction in skin temperature in the left ischemic hindlimb (arrowheads in the lower 
panel), as evidenced by the elevation of laterality in temperature (0.96 r 0.04, P < 0.01, 
n = 9). 
 
Figure 4 
Donepezil increases VEGF expression in the heart. 
(A) VEGF immunoreactivity was more in the heart of donepezil-treated WT than in that 
of untreated WT. Scale bars represent 50 Pm. Cardiac expression of the VEGF protein 
was more enhanced by donepezil (P < 0.01, n = 9). (B) More VEGF-positive signals 
were also detected in donepezil-treated D7 KO than in untreated D7 KO. A magnified 
view is shown in (A) and (B), which demonstrates the capillary-like appearance. Scale 
bars represent 50 Pm. (C) Donepezil (1 PM) increased ChAT protein expression in 
HUVECs within 10 h, (P < 0.01, n = 6). (D) mRNA expression of m2, D4, and D7 in 
HUVECs increased with donepezil within 24 h. In contrast, both D3 and GAPDH 
mRNA expression was not elevated. (E) Caspase 3/7 activity decreased significantly 
with a 24 h donepezil treatment (1 PM) in the case of depletion of growth factors (69.3 
r 3.8 % vs. control, P < 0.01, n = 6); however, MTT activity was not affected by 
donepezil (NS).  
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